Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders : current practice in Europe 2009
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
1192866
Author(s)
Ljungman, P; Bregni, M; Brune, M; Cornelissen, J; de Witte, T; Dini, G; Einsele, H; Gaspar, H B; Gratwohl, A; Passweg, J; Peters, C; Rocha, V; Saccardi, R; Schouten, H; Sureda, A; Tichelli, A; Velardi, A; Niederwieser, D; European Group for Blood and Marrow Transplantation
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders : current practice in Europe 2009
Journal
Bone marrow transplantation
Volume
45
Number
2
Pages / Article-Number
219-34
Keywords
haematopoietic SCT, indications, recommendations, Europe
Abstract
The European Group for Blood and Marrow Transplantation regularly publishes special reports on the current practice of haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major changes have occurred since the first report was published. HSCT today includes grafting with allogeneic and autologous stem cells derived from BM, peripheral blood and cord blood. With reduced-intensity conditioning regimens in allogeneic transplantation, the age limit has increased, permitting the inclusion of older patients. New indications have emerged, such as autoimmune disorders and AL amyloidosis for autologous HSCT and solid tumours, myeloproliferative syndromes and specific subgroups of lymphomas for allogeneic transplants. The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented.
